Dr. Zagaja on Major Benefit With Prostatectomy
November 1st 2016Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer
October 31st 2016Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Combo Trials Aim to Clarify Optimal Radium-223 Use in mCRPC
August 16th 2016Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC
August 11th 2016Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer
August 11th 2016Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.
Expert Stresses Importance of PSA-Based Screening in Early-Stage Prostate Cancer
July 21st 2016Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.
Stadler Shares Treatment Updates, Questions in Castration-Sensitive Prostate Cancer
July 12th 2016Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.
Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer
May 19th 2016Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.
Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer
March 28th 2016Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.
Checkpoint Inhibitors Show Promise in Triple-Negative Breast Cancer
Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.